Clinical Trial Update: Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating sensitization of non-M3 acute myeloid leukemia blasts to all-trans retinoic acid using epigenetic treatment with tranylcypromine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Tranylcypromine (tranylcypromine)

Snippet

Sponsor: Michael Luebbert | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: UNKNOWN